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Abstract
Chlorogenic acids (CGA) are the most abundant polyphenols in coffee. Continuous consumption of CGA reduces body fat and body weight.
Since energy metabolism and sleep are controlled by common regulatory factors, consumption of CGA might modulate sleep. Lack of sleep
has been identiﬁed as a risk factor for obesity, hypertension and type 2 diabetes. The aim of this study was to determine the effects of ingesting
CGA over 5 d on energy metabolism and sleep quality in humans. A total of nine healthy subjects (four male and ﬁve female) completed a
placebo-controlled, double-blinded, cross-over intervention study. Subjects consumed a test beverage containing 0 or 600mg of CGA for 5 d.
On the ﬁfth night, subjects stayed in a whole-room metabolic chamber to measure energy metabolism; sleep was evaluated using
polysomnographic recording. It was found that CGA shortened sleep latency (9 (SEM 2) v. 16 (SEM 4)min, P< 0·05) compared with the control,
whereas no effect on sleep architecture, such as slow-wave sleep, rapid eye movement or waking after sleep onset, was observed.
Indirect calorimetry revealed that consumption of CGA increased fat oxidation (510 (SEM 84) kJ/8 h (122 (SEM 20) kcal/8 h) v. 331 (SEM 79) kJ/8 h
(81 (SEM 19) kcal/8 h), P< 0·05) but did not affect energy expenditure during sleep. Consumption of CGA enhanced parasympathetic activity
assessed from heart-rate variability during sleep (999 (SEM 77) v. 919 (SEM 54), P< 0·05). A period of 5-d CGA consumption signiﬁcantly
increased fat oxidation during sleep, suggesting that beverages containing CGA may be beneﬁcial to reduce body fat and prevent obesity.
Consumption of CGA shortened sleep latency and did not adversely affect sleep quality.
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Coffee is one of the most widely consumed beverages throughout
the world, and its origin dates back to the ﬁfteenth century or
earlier(1). Epidemiological studies have identiﬁed coffee con-
sumption as a factor associated with reduced risks of type 2
diabetes(2,3), liver cirrhosis(4), Alzheimer’s disease(5) and Parkin-
son’s disease(6). The coffee bean, and especially the green coffee
bean, is known to be a rich source of biologically active
compounds such as polyphenolic antioxidants including
5-caffeoylquinic acid (5-CQA) (formerly called 3-CQA or chloro-
genic acid (CGA))(7), 3-CQA, 4-CQA, 3,4-dicaffeoylquinic acid
(3,4-diCQA), 3,5-diCQA, 4,5-diCQA, 3-feruloylquinic acid
(3-FQA), 4-FQA, and 5-FQA, which consist of CGA(8,9).
Recent human studies have shown that daily consumption of
340–600mg/d of CGA (equivalent to one–two cups of coffee(10))
induced favourable effects on fat oxidation(11) and lowered
postprandial glucose(12) and insulin resistance(13) as well as had
favourable effects on endothelial functions(14,15) and mood
enhancement(16). Accumulating evidence has suggested that CGA
exhibit many biological properties including antioxidant(17), anti-
obesity(18), hypoglycaemic and hypolipidaemic effects(19). More-
over, a recent study demonstrated that CGA exerts anti-amnesic
activity via inhibition of acetylcholinesterase and malondialdehyde
in the hippocampus and frontal cortex(20). Foods and associated
bioactive substances often affect multiple physiological functions,
as exempliﬁed by caffeine acting on the autonomic nervous
system(21), energy metabolism(22,23) and sleep(24). Cross-talk
between physiological functions exists within the body, and
several lines of evidence suggest a link between sleep, the
autonomic nervous system and energy metabolism(25). Neuro-
substances such as orexin, leptin and melatonin act on sleep and
Abbreviations: CGA, chlorogenic acids; CON, control; CQA, caffeoylquinic acid; diCQA, dicaffeoylquinic acid; E%, energy percentage; FQA, feruloylquinic acid.
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wakefulness and on energy balance(26–28). The effects of CGA
ingestion on carbohydrate and fat metabolism warrant additional
studies evaluating the effects of CGA ingestion on sleep, the lack
of which has been identiﬁed as a risk factor for, amongst other
conditions, obesity, hypertension and type 2 diabetes(29–31).
Metabolites of CGA potentiated pentobarbital-induced sleep by
prolonging sleeping time and shortening sleep latency(32), but
the effects of consuming CGA on human sleep have not been
studied.
The present study evaluated the effects of ingesting 600mg of
CGA on sleep architecture, energy metabolism and autonomic
nervous function in healthy male and female subjects. Simul-
taneous measurements of sleep architecture and respiratory
analysis could provide new insights regarding which CGA
exert possible sleep and energy metabolism improvements.
To evaluate energy metabolism during sleep, whole-room
indirect calorimetry was adopted, which provides a controlled
environment in which energy metabolism can be continuously
measured for a long period, including during sleep.
Methods
Subjects
In all, four healthy male subjects and ﬁve healthy female sub-
jects with a mean age of 25·7 years and BMI of 21·8 kg/m2
participated in this study. Subjects had normal sleeping proﬁles
based on the Pittsburgh sleep quality index (≤5). No subject
had engaged in regular exercise more than twice a week or
used any regular or temporary medication. Exclusion criteria for
the subjects were a clinical diagnosis of sleep apnoea hypopnea
syndrome, a medical or psychiatric condition, smokers and shift
workers. Subjects who drank more than a bottle of alcohol
(350ml) per day were also excluded from the study. For female
subjects, those with a severe menstrual cycle problem and those
who were pregnant were excluded. One female subject was
excluded from the statistical analysis of energy metabolism
because of mechanical trouble (unstable ﬂow control of the
metabolic chamber) during the trial with CGA. This study was
conducted according to the guidelines laid down in the
Declaration of Helsinki and all procedures involving human
subjects were approved by the Ethics Committee of the
University of Tsukuba. All subjects provided written informed
consent before study commencement; the protocol was
registered with Clinical Trials UMIN, ID no.: UMIN000022889.
Protocol
The present study was a placebo-controlled, double-blinded,
cross-over intervention study. During each 5-d session, a test
beverage containing 0 (control (CON)) or 600mg of CGA was
consumed 10min before bedtime and subjects were asked to
refrain from ingesting beverages containing caffeine and
alcohol. During the study, the subjects maintained their usual
activities and dietary habits, which were conﬁrmed by acti-
graphy recording and a daily diary. On days 3–5, the subjects
ingested speciﬁed meals for breakfast, lunch and dinner, which
were provided by the study coordinators.
On the 5th day, subjects consumed lunch in the laboratory
and stayed indoors. After consuming dinner, subjects entered
the whole-room metabolic chamber and remained sedentary.
Subjects went to bed at their usual bedtime and slept for 8 h.
Energy metabolism was measured for 16 h (from 3 h before
bedtime on the 5th day to 5 h after waking the next morning).
The meals provided in the laboratory were based on energy
requirements estimated from the BMR equation(33) with a
physical activity level of 1·3. The meal composition (energy
percentage (E%)) was 15 E% protein, 25 E% fat and 60 E%
carbohydrates, and both groups received meals identical in
quantity and composition. The energetic distribution was 30 E%
for breakfast, 30 E% for lunch and 40 E% for dinner.
The experiment was preceded by an adaptation night in the
metabolic chamber, during which the sensors and electrodes of
the polysomnographic recording system were attached to the
subjects. The two trials were separated by a washout period of
2–4 weeks, and studies with female subjects were performed
during the same phase of the menstrual cycle; three female
subjects were evaluated during the follicular phase and the other
two female subjects were evaluated during the luteal phase.
Beverages
The CGA and placebo test beverages were prepared to be indis-
tinguishable on the basis of appearance and ﬂavour, and were
canned (100ml). All CGA isomers are presented according to the
IUPAC nomenclature(9). The test beverage contained 0 or 600mg
of CGA, which consisted of CQA (68%), FQA (14%) and diCQA
(19%) (Table 1). CGA were prepared from green coffee beans
using hot water extraction followed by spray drying and girding.
After activated carbon ﬁltration, caffeine was not detected
(<0·5mM). The CGA composition in test beverages was measured
by HPLC with a UV detector (325nm). All peaks of the isomers
were conﬁrmed by LC-MS(34). The standard, 5-CQA, was
purchased from Sigma, and other standards, 3-CQA, 4-CQA,
3-FQA, 4-FQA, 5-FQA, 3,4-diCQA, diCQA and 3,5-diCQA, were
obtained by repeated fractionations of green coffee bean extract
(purity >96%, conﬁrmed by LC-UV detection and 1H-NMR)
using preparative chromatography with an octa decyl silyl (ODS)
column(34). Both beverages were caffeine-free, and the energy
contents were 29kJ/100ml (7kcal/100ml) and 8kJ/100ml
(2kcal/100ml) in the CGA and placebo beverages, respectively.
Table 1. Chlorogenic acid (CGA) compositions of the test beverages
(mg/100ml)
CON CGA
3-CQA 0·0 117·5
4-CQA 0·0 120·6
5-CQA 0·0 187·1
3-FQA 0·0 22·7
4-FQA 0·0 24·0
5-FQA 0·0 39·9
3,5-diCQA 0·0 28·4
3,4-diCQA 0·0 45·7
4,5-diCQA 0·0 43·7
Total 0·0 629·6
CON, control; CQA, caffeoylquinic acid; FQA, feruloylquinic acid; diCQA,
dicaffeoylquinic acid.
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Sleep recording
The recording system consisted of four electroencephalography
derivations (C3-A2, C4-A1, O2-A1, and O1-A2), submental
electromyography and bilateral electro-oculography using a
PSG-1100 (Nihon Kohden). Sleep parameters were classiﬁed in
30-s intervals as wakefulness and stage 1, stage 2, slow-wave
sleep (SWS), and rapid eye movement (REM) sleep according to
the method developed by Rechtschaffen & Kales(35). In addi-
tion, total sleep time, sleep onset latency, REM sleep latency
and sleep efﬁciency percentages were measured.
Data analysis: spectral analysis of the
electroencephalogram
The C3-A2 electroencephalogram (EEG) recording was ana-
lysed using discrete fast Fourier transform techniques. The fast
Fourier transform was conducted on an EEG record length of 5 s
to obtain a frequency resolution of 0·2Hz. Each 5-s segment of
the EEG signal was ﬁrst windowed with a Hanning tapering
window before computing the power spectra. The spectral
distribution was categorised into the following frequency
bands: delta (0·75–4·00Hz), theta (4·10–8·00Hz), alpha
(8·10–12·00Hz), sigma (12·10–14·00Hz) and beta (14·10–
30·00Hz). The power content of the delta band for each 30-s
epoch of sleep was determined as the average power across the
six 5-s segments of the EEG (expressed as µV2)(36).
Indirect calorimetry
The airtight metabolic chamber measures 2·00×3·45×2·10m
(FHC-15S; Fuji Medical Science Co., Ltd), and was used from day 5,
4h before bedtime, to day 6, 5h after waking (total, 16h). Air in the
chamber is pumped out at a rate of 80 litres/min. The temperature
and relative humidity of incoming fresh air were controlled at 25°C
and 55%, respectively. The chamber was furnished with an
adjustable hospital bed, desk, chair and toilet. Concentrations of O2
and carbon dioxide (CO2) in outgoing air were measured with high
precision by online process MS (VG Prima δB; Thermo Electron
Co.). The precision of MS, deﬁned as the standard deviation for
continuous measurement of the calibrated gas mixture (O2, 15%;
CO2, 5%), was 0·0016% for O2 and 0·0011% for CO2. Every
minute, VO2 and CO2 production (VCO2) rates were calculated
using an algorithm for improved transient response(37). Oxidation
of macronutrients and energy expenditure were calculated from
VO2, VCO2 and urinary N excretion
(38). Rates of N, an index of
protein oxidation, were assumed to be constant during calorimetry:
Glucose oxidation g=minð Þ= 455VCO2 ðlitres=minÞ
 321VO2 ðlitres=minÞ
 287N ðg=minÞ:
Fat oxidation g=minð Þ= 167VO2 ðlitres=minÞ
 167VCO2 ðlitres=minÞ
 192N ðg=minÞ:
Protein oxidation ðg=minÞ= 625N ðg=minÞ:
Once the rates of glucose, fat and protein oxidation had been
computed, the total rate of energy production could be esti-
mated by taking energetic equivalents of the three substrates
into account. Conversion factors for energetic equivalents were
17·15 kJ/g (4·10 kcal/g) for protein (107·215 kJ/g (25·625 kcal/g)
for urinary N), 15·65 kJ/g (3·74 kcal/g) for carbohydrates and
39·75 kJ/g (9·50 kcal/g) for fat(38).
Autonomic nervous system activity
The R-R intervals of the electrocardiogram were continuously
monitored using a telemetric heart-rate monitor (LX−3230, 207;
Fukuda Denshi Co., Ltd) and the power spectrum of heart-rate
variability was estimated using the maximum entropy method. The
spectra measured were computed as amplitudes (i.e. areas under
the power spectra) and are presented in ms2. Parasympathetic and
sympathetic nervous system activities were estimated at a high
frequency (HF; 0·15−0·4Hz) and as the power ratio of low fre-
quency (LF; 0·04−0·15Hz):high frequency (LF:HF), respectively(39).
Statistical analysis
Results are expressed as means with their standard errors.
Sample size was calculated on the basis of a power analysis
using previous data. A study group of nine subjects was
required for a power of 80% at a two-sided α of 0·05. We
performed a power analysis; the actual power was >80% for
each comparison. Paired t tests were used to compare values of
energy metabolism, sleep parameters and autonomic nervous
system activity between the groups. The effects of CGA on the
time course of autonomic nervous system activity were assessed
by a two-way repeated measures ANOVA and a Bonferroni
multiple comparison. Differences were considered signiﬁcant
when the error probability was <0·05.
Results
Body weight, BMI and body fat did not change during the 5-d
trial with control and CGA beverages (Table 2). Sleep archi-
tecture (lengths of stage 1, stage 2, SWS, REM and wakefulness
after sleep onset) was similar between the trials, except that
sleep latency was shorter in trials with ingestion of CGA
(Table 3). The time course of delta power, a quantitative index
of SWS, was similar between the two trials, but those during the
1st hour of sleep during CGA trials tended to be higher than
those during CON trials. A two-factor repeated measures
ANOVA identiﬁed a signiﬁcant interaction effect. The average
delta power during the 1st hour (CON: 29 165 (SEM 5711) µV2 v.
CGA: 40 758 (SEM 5128) µV2, P= 0·08) seemed to be higher in
the CGA trials than in the CON trials, but no statistically sig-
niﬁcant difference was found in multiple comparisons (Fig. 1).
The average sympathetic nervous system activity during 16h
of calorimetry was similar (CON: 2·20 (SEM 0·09) v. CGA: 2·36
(SEM 0·16)), but parasympathetic nervous system activity was
enhanced by CGA consumption (CON: 919 (SEM 55)ms2 v. CGA:
999 (SEM 78)ms2, P< 0·05). Visual inspection of the time course of
autonomic nervous system activity suggests that parasympathetic
activity and sympathetic activity increased during the second half
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of sleep and after awakening, respectively, by CGA consumption
(Fig. 2). However, a statistically signiﬁcant difference was not
detected by a two-factor repeated measures ANOVA.
Fat oxidation during sleep (8h) was higher in trials with
chlorogenic ingestion than in control trials (Fig. 3). The differ-
ence in fat oxidation was also signiﬁcant when entire 16-h
calorimetry periods were compared (CON: 638·5 (SEM 118·4) kJ/
16 h (152·6 (SEM 28·3) kcal/16 h) v. CGA: 958·1 (SEM 152·7) kJ/16 h
(229·0 (SEM 36·5) kcal/16 h), P< 0·05). Energy expenditure was
similar under both conditions, and the difference in carbohydrate
oxidation was not statistically signiﬁcant. Urinary N excretion as
a marker of protein catabolism was similar between the two
experimental conditions.
Discussion
In the present study, we assessed whether ingestion of beverages
containing CGA for over 5 d had any effect on sleep, autonomic
Table 2. Anthropometric variables before and after ingesting either the
chlorogenic acids (CGA) or placebo beverage for 5 d*
(Mean values with their standard errors)
Initial 5 d
Mean SEM Mean SEM
Body weight (kg)
Placebo group 63·9 3·2 64·0 3·2
CGA group 62·9 3·0 63·3 3·0
BMI (kg/m2)
Placebo group 21·8 0·5 22·1 0·5
CGA group 21·7 0·5 21·9 0·5
Body fat (%)
Placebo group 24·6 2·3 25·1 2·2
CGA group 23·8 2·1 24·6 2·2
* Mean values did not differ significantly between the groups.
Table 3. Sleep architecture
(Mean values with their standard errors)
CON CGA
Parameters Mean SEM Mean SEM P
Total bedtime (min) 480·0 480·0
Total sleep time (min) 436·2 4·2 444·2 3·9 0·268
Wakefulness (min) 27·9 4·3 26·7 4·0 0·840
Sleep latency (min) 15·6 4·5 8·7 2·7 0·043*
Sleep efficiency (%) 90·9 0·9 92·5 0·8 0·275
Stage 1 (min) 58·4 7·0 56·7 4·3 0·792
Stage 2 (min) 274·1 10·4 279·8 11·8 0·428
SWS (min) 15·7 5·6 19·2 5·8 0·256
REM sleep (min) 87·8 7·0 88·3 6·7 0·956
CON, control; CGA, chlorogenic acids; SWS, slow-wave sleep; REM, rapid eye
movement.
* P<0·05.
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Fig. 1. The delta power of the sleep electroencephalogram after 5 d of
ingestion of the chlorogenic acids beverage (●) or placebo beverage (○) is
shown. Values are means (n 9 per group), with standard errors.
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Fig. 2. Sympathetic (a) and parasympathetic (b) nervous system activities
during calorimetry after 5 d of ingestion of the chlorogenic acids beverage (●)
or placebo beverage (○) are shown. Values are means (n 9 per group), with
standard errors. LF, low frequency, HF, high frequency.
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Fig. 3. Energy expenditure and substrate oxidation during sleep after 5 d of
ingestion of the chlorogenic acids beverage (■) or placebo beverage (□).
Values are means (n 8 per group), with standard errors represented by vertical
bars. *P< 0·05.
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nervous system activity or energy metabolism in healthy humans.
Our ﬁndings revealed that CGA shortened sleep latency as
opposed to the controls, whereas no effect on sleep architecture
such as SWS, REM or waking after sleep onset was observed.
Indirect calorimetry revealed that consumption of CGA increased
fat oxidation but did not affect energy expenditure during sleep.
Consumption of CGA enhanced parasympathetic activity, which
was assessed on the basis of heart-rate variability. These results
support the possibility that beverages containing CGA possess
beneﬁcial effects to prevent obesity and improve sleep.
Fat oxidation during sleep was increased by consumption of
CGA. An animal experiment reported an inhibitory effect of the
green coffee bean extract, which is rich in CGA and its related
compounds, on visceral fat accumulation and body weight gain
in mice. CGA and its related compounds up-regulated carnitine
palmitoyltransferase activity in the liver(40). Using continuous
and prolonged indirect calorimetry, the present study conﬁrmed
the ﬁndings of a previous report on use of indirect calorimetry
for a short duration (3·5 h), which showed increased fat
oxidation after ingestion of CGA (359mg)(41). These indirect
calorimetry ﬁndings are consistent with another human study
reporting that daily consumption of coffee enriched with CGA
for 12 weeks resulted in body weight reduction(42).
The effect of CGA in stimulating fat oxidation during sleep was
manifested without an adverse effect on sleep architecture,
which is in contrast with the effects of sympathomimetics such as
capsaicin, catechins and caffeine. Capsaicin, in addition to
stimulating epinephrine secretion, acts as a transient receptor
potential cation channel subfamily V member 1 agonist(43) and
disturbs sleep via changes in body temperature. Caffeine, in
addition to inhibiting the phosphodiesterase-induced degrada-
tion of intracellular cyclic AMP, acts as an adenosine A2A receptor
antagonist and increases wakefulness(44). Effects of catechins,
which inhibit norepinephrine degradation, on sleep remain to be
evaluated. A potential mediator of CGA that can shorten sleep
latency is ferulic acid, which is a metabolite of CGA; ferulic acid
also potentiates pentobarbital-induced sleep in mice by
prolonging sleeping time and shortening sleep latency in a dose-
dependent manner(32). At 1-2 h after the oral ingestion of CGA,
they are metabolised via methylation and appear as ferulic acids
in plasma(34,45). Contrary to the present human study, sleep
latency in rats was signiﬁcantly increased by ingestion of CGA
(CGA, 500mg/kg and caffeic acid, 200mg/kg)(46). The dose of
CGA in the animal experiment was several orders of magnitude
greater than that in the present human study. Human subjects, as
opposed to experimental animals, were exposed to CGA via
daily consumption of coffee and vegetables.
The function of the autonomic nervous system was also affected
by ingestion of CGA through up-regulation of parasympathetic
nervous system activity and a decrease in heart rate. An increase in
parasympathetic nervous system activity may explain the anti-
hypertensive effects of CGA, for which several mechanisms have
been proposed: reduction of free radical production, scavenging
free radicals, stimulation of NO production and inhibition of
angiotensin-converting enzyme(47). In addition to vasodilation
effects in peripheral tissue, NO acts as a neuromodulator within
the central and peripheral nervous systems, and modulates sym-
pathetic and parasympathetic activities(48). Close inspection of the
time courses of sympathetic nervous system activity revealed the
following. First, before and during the ﬁrst 3h of sleep,
activities of the sympathetic and parasympathetic nervous systems
were similar between the trials. The mechanism by which inges-
tion of CGA shortened sleep latency cannot be explained by the
effect of chlorogenic ingestion on autonomic nervous system
activity. Second, relative to that in the placebo-control trial, para-
sympathetic activity was higher during the second half of sleep,
whereas sympathetic activity was higher after awakening in the
morning in trials with ingestion of CGA. Thus, ingestion of CGA
induced a greater decrease in parasympathetic activity and
increase in sympathetic activity after awakening.
In conclusion, ingestion of CGA stimulated fat oxidation
without an adverse effect on sleep architecture; rather, it shor-
tened sleep latency. Ingestion of CGA increased parasympathetic
activity during sleep, and the causal relation to its effects on sleep
and fat oxidation remains to be evaluated. To generalise the
present ﬁndings, an experiment with a larger sample size of
obese and/or aged subjects should be performed.
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